GSK Teams With Biotech Co. On $350M Cancer Drug Venture
London biotechnology company Adaptimmune Ltd. said Monday that it has teamed up with U.K. pharmaceutical giant GlaxoSmithKline PLC to develop an early stage cancer drug, inking a deal that is potentially...To view the full article, register now.
Already a subscriber? Click here to view full article